With $6 million in the bank as a result of a summertime Series C round, Saegis Pharmaceuticals Inc. has completed a Phase IIa study and may consider a Series D round in 2006, President and Chief Executive Rodney Pearlman told VentureWire. http://www.saegispharma.com
